Identification of drug candidates and repurposing opportunities through compound–target interaction networks
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: System-wide identification of both on- and off-targets of chemical probes provides improved understanding of their therapeutic potential and possible adverse effects, thereby accelerating and de-risking drug discovery process. Given the high costs of experimental profiling of the complete target space of drug-like compounds, computational models offer systematic means for guiding these mapping efforts. These models suggest the most potent interactions for further experimental or pre-clinical evaluation both in cell line models and in patient-derived material. AREAS COVERED: The authors focus here on network-based machine learning models and their use in the prediction of novel compound-target interactions both in target-based and phenotype-based drug discovery applications. While currently being used mainly in complementing the experimentally mapped compound-target networks for drug repurposing applications, such as extending the target space of already approved drugs, these network pharmacology approaches may also suggest completely unexpected and novel investigational probes for drug development. EXPERT OPINION: Although the studies reviewed here have already demonstrated that network-centric modeling approaches have the potential to identify candidate compounds and selective targets in disease networks, many challenges still remain. In particular, these challenges include how to incorporate the cellular context and genetic background into the disease networks to enable more stratified and selective target predictions, as well as how to make the prediction models more realistic for the practical drug discovery and therapeutic applications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lamb, J., Crawford, E. D., Peck, D., Modell, J. W., Blat, I. C., Wrobel, M. J., Lerner, J., Brunet, J.-P., Subramanian, A., Ross, K. N., et al. (2006) · Science · doi:10.1126/science.1132939 · Cited by 5,257
Comprehensive analysis of kinase inhibitor selectivity
Davis, M. I., Hunt, J. P., Herrgard, S., Ciceri, P., Wodicka, L. M., Pallares, G., Hocker, M., Treiber, D. K., & Zarrinkar, P. P. (2011) · Nature Biotechnology · doi:10.1038/nbt.1990 · Cited by 2,409
Relating protein pharmacology by ligand chemistry
Keiser, M. J., Roth, B. L., Armbruster, B. N., Ernsberger, P., Irwin, J. J., & Shoichet, B. K. (2007) · Nature Biotechnology · doi:10.1038/nbt1284 · Cited by 2,402
Diagnosing the decline in pharmaceutical R&D efficiency
Scannell, J. W., Blanckley, A., Boldon, H., & Warrington, B. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3681 · Cited by 1,981 · cited 1×
“However, despite the continuous increase in the number of promising therapeutic targets, the amount of new drugs approved by US FDA per billion dollars (inflation-adjusted) spent on R&D has halved every 9 years since 1950 [1].”
BackgroundPredicting new molecular targets for known drugs
Keiser, M. J., Setola, V., Irwin, J. J., Laggner, C., Abbas, A. I., Hufeisen, S. J., Jensen, N. H., Kuijer, M. B., Matos, R. C., Tran, T. B., et al. (2009) · Nature · doi:10.1038/nature08506 · Cited by 1,667 · cited 1×
“, in which DTIs are inferred statistically by comparing structural similarities between drugs and known set of ligands for a given target [38,39].”
BackgroundThe support of human genetic evidence for approved drug indications
Nelson, M. R., Tipney, H., Painter, J. L., Shen, J., Nicoletti, P., Shen, Y., Floratos, A., Sham, P. C., Li, M. J., Wang, J., et al. (2015) · Nature Genetics · doi:10.1038/ng.3314 · Cited by 1,666 · cited 1×
“There exist pilot studies showing the potential of GWAS findings for generating hypotheses about potential drug--disease links for both drug repurposing or target validation applications [56,58-60].”
BackgroundDrug target identification using side-effect similarity
Campillos, M., Kuhn, M., Gavin, A.-C., Jensen, L. J., & Bork, P. (2008) · Science · doi:10.1126/science.1158140 · Cited by 1,248 · cited 1×
“, where the authors used phenotypic side-effect similarities in the inference of compound--target connections, several of which were tested and confirmed with in vivo assays [47].”
BackgroundTracking cancer drugs in living cells by thermal profiling of the proteome
Savitski, M. M., Reinhard, F. B. M., Franken, H., Werner, T., Savitski, M. F., Eberhard, D., Molina, D. M., Jafari, R., Dovega, R. B., Klaeger, S., et al. (2014) · Science · doi:10.1126/science.1255784 · Cited by 1,187 · cited 1×
“devised a more general approach for proteome-wide monitoring of protein--ligand binding directly in living cells by combining the technique of cellular thermal shift assay with quantitative mass spectrometry (MS) [28].”
MethodCRISPR/Cas9-mediated gene editing in human tripronuclear zygotes
Liang, P., Xu, Y., Zhang, X., Ding, C., Huang, R., Zhang, Z., Lv, J., Xie, X., Chen, Y., Li, Y., et al. (2015) · Protein & Cell · doi:10.1007/s13238-015-0153-5 · Cited by 1,135 · cited 1×
“These exciting genome-engineering tools may even provide effective and safe therapeutic applications in the future, provided that RNAi-based delivery or CRISPR/ Cas9 systems can be improved in terms of their fidelity and selectivity to target a specific part and tissue context of the disease network only [70,71].”
BackgroundUnderstanding multicellular function and disease with human tissue-specific networks
Greene, C. S., Krishnan, A., Wong, A. K., Ricciotti, E., Zelaya, R. A., Himmelstein, D. S., Zhang, R., Hartmann, B. M., Zaslavsky, E., Sealfon, S. C., et al. (2015) · Nature Genetics · doi:10.1038/ng.3259 · Cited by 832
Cited by
Network Pharmacology Approach for Medicinal Plants: Review and Assessment
Noor, F., Tahir ul Qamar, M., Ashfaq, U. A., Albutti, A., Alwashmi, A. S. S., & Aljasir, M. A. (2022) · Pharmaceuticals · doi:10.3390/ph15050572 · Cited by 540
Machine learning approaches and databases for prediction of drug–target interaction: a survey paper
Bagherian, M., Sabeti, E., Wang, K., Sartor, M. A., Nikolovska-Coleska, Z., & Najarian, K. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbz157 · Cited by 429
Design of efficient computational workflows for in silico drug repurposing
Vanhaelen, Q., Mamoshina, P., Aliper, A. M., Artemov, A., Lezhnina, K., Ozerov, I., Labat, I., & Zhavoronkov, A. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2016.09.019 · Cited by 150
Pizzorno, A., Padey, B., Terrier, O., & Rosa-Calatrava, M. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00531 · Cited by 122
“These in silico methods include the screening of chemical, biological, and text databases, analysis of quantitative structure-activity relationships, pharmacophores, homology models, and other molecular modeling approaches as well as network analysis of biological functions, machine learning and almost any other analy…”
MethodAlternative strategies in cardiac preclinical research and new clinical trial formats
Kreutzer, F. P., Meinecke, A., Schmidt, K., Fiedler, J., & Thum, T. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvab075 · Cited by 36
“224 As an example of computer simulations, the Virtual Human Physiology project started in 2005 to translate computational physiology into clinical practice.”
Method
Metadata
- Authors
- Cichonska, A., Rousu, J., & Aittokallio, T.
- Venue
- Expert Opinion on Drug Discovery
- Publisher
- Informa Healthcare
- Published
- 2015-10
- Volume
- 10
- Issue
- 12
- Pages
- 1333-1345
- ISSN
- 1746-0441 (ISSN-L)
- 1746-045X
- OpenAlex
- W1928552520
- Cited by
- 65
- References
- 15
- FWCI
- 6.99
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Identification of drug candidates and repurposing opportunities through compound–target interaction networks. https://app.cochat.ai/papers/10.1517/17460441.2015.1096926
- The paper
- Cichonska, A., Rousu, J., & Aittokallio, T. (2015). Identification of drug candidates and repurposing opportunities through compound–target interaction networks. Expert Opinion on Drug Discovery. https://doi.org/10.1517/17460441.2015.1096926
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.